Zobrazeno 1 - 10
of 3 627
pro vyhledávání: '"Event Reporting"'
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-15 (2024)
Abstract Background Combining immune checkpoint and proton pump inhibitors is widely used in cancer treatment. However, the drug-drug interactions of these substances are currently unknown. This study aimed to explore drug-drug interactions associate
Externí odkaz:
https://doaj.org/article/5fe85e835f69445692ad453ca97b9064
Autor:
Seong Kyung Kim, Myeong Gyu Kim
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract This study aimed to evaluate the association between sacubitril/valsartan and dementia-related adverse events (AEs) in geographical subpopulations using subgroup disproportionality analysis. Cases from the FDA adverse event reporting system
Externí odkaz:
https://doaj.org/article/31541ee1e2c540899c7ba7d8915116f0
Publikováno v:
Prizren Social Science Journal, Vol 8, Iss 2, Pp 63-71 (2024)
This study was designed to investigate patient falls in a university hospital within the scope of patient safety according to variables such as age, gender, time interval when the fall occurred, clinic/polyclinic etc. where the fall occurred and the
Externí odkaz:
https://doaj.org/article/e2318b74243e496885682f7575e0ca08
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Trastuzumab emtansine (T-DM1) is widely utilized as a second-line and subsequent treatment for metastatic HER2+ breast cancer and has shown promise in early breast cancer treatment, particularly in adjuvant settings for residual disease afte
Externí odkaz:
https://doaj.org/article/cf8ea2b8612645708a91c061907a0d54
Autor:
Madeleine Alvarez
Publikováno v:
Frontiers in Nuclear Medicine, Vol 4 (2024)
A previously published paper in the official journal of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) concluded that the artificial intelligence chatbot ChatGPT may offer an adequate substitute for nuclear medicine staff informational
Externí odkaz:
https://doaj.org/article/38bc10b498444ee89ea46ec9fc7fe633
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundThe discovery and development of immune checkpoint inhibitors (ICIs) have resulted in their application as a novel therapeutic strategy for patients with small-cell lung cancer (SCLC). However, a comprehensive analysis of the potential adve
Externí odkaz:
https://doaj.org/article/5ae4c212c0f64944b6212f9b26ad5e1c
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundAbraxane plays a crucial role in the treatment of various types of cancer, despite the considerable attention it has garnered for its adverse drug events (ADEs). Nevertheless, there is currently a significant lack of comprehensive real-worl
Externí odkaz:
https://doaj.org/article/bf3d92cde70348f183ff0f131c49423f
Autor:
Qiuyu Xu, Lin Jiang, Gang Chen, Sanxi Ai, Xiaohong Fan, Gangan Wang, Chunyu Jia, Jiahui Wang, Ke Zheng, Bin Zhao, Yan Qin, Xuemei Li
Publikováno v:
Frontiers in Medicine, Vol 11 (2024)
ObjectivePoly (ADP-ribose) polymerase inhibitors (PARPis) are emerging targeted therapeutic agents in oncology, primarily indicated for ovarian and metastatic breast cancer. Acute kidney injury (AKI) has been observed in patients undergoing PARPi tre
Externí odkaz:
https://doaj.org/article/3cdef92e92234ccaa10f0c90bd29ed27
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundUnderstanding the risk relationship between statin use and immune-related adverse events (irAEs) in patients undergoing immune checkpoint inhibitors (ICIs) therapy is crucial for optimizing oncological management.ObjectiveThis study aimed t
Externí odkaz:
https://doaj.org/article/b137d2ea6435474c81af64f6c1136dae
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
BackgroundInhibitors of the anaplastic lymphoma kinase (ALK) gene mutation are first-line treatments in patients with ALK-positive lung cancer. The FDA label warns of the risk of interstitial lung disease (ILD) in patients receiving ALK TKIs. However
Externí odkaz:
https://doaj.org/article/de1bea835ce7457f820904a608365a79